Market Synopsis
An increase in healthcare
expenditure in developing countries is expected to drive the growth of the
global diabetic ulcer treatment market.
Strategic mergers & acquisitions
are also likely to boost market growth with companies looking to strengthen
their market positioning, increase their product portfolios, and improve their
brand goodwill. For instance, in May 2019, 3M announced the acquisition of
Acelity L.P.Inc. and its KCI subsidiaries for approximately USD 6.7
billion. The acquisition would help 3M strengthen its position in the global
diabetic ulcer treatment market.
Market Influencer
Increased spending on
healthcare. Diabetic ulcer treatment accounted for an estimated hospitalization
or amputation costs of USD 35,000 to USD 45,000 in Australia, Europe, and the
Americas, and around USD 5,000 in developing countries.
Market Highlights
According to MRFR analysis, the global diabetic ulcer
treatment market is expected to register a CAGR of 8.50% during the forecast
period of 2019 to 2025 and would value USD 7500 Million by 2025.
The Diabetic Ulcer Treatment Market
affects the movement or musculoskeletal systems such as muscles, tendons, and
ligaments. These disorders are also known as repetitive motion injuries.
Diabetic ulcer treatment can arise by making the same motion repeatedly or
lifting heavy objects. They affect different parts of the body, mainly the
upper and lower back and neck.
The growth of global the diabetic ulcer treatment
market is driven by various factors such as increasing global geriatric patient
population, rising prevalence, and rising prevalence rate of diabetic foot
ulcer patients. However, high costs of diabetic ulcer treatment and unmet
medical need for diabetic ulcer in underdeveloped regions are expected to curb
the growth of the global diabetic ulcer treatment market.
The global diabetic ulcer treatment market is
currently dominated by several market players. The key players are involved in
product launches and strategic collaborations to strengthen their market
positions.
Regional Analysis
The market has been divided, by region, into the
Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas
is expected to be the largest market owing to the increasing prevalence of
diabetic ulcer treatment and rising per capita healthcare expenditure. The
diabetic ulcer treatment market in the Americas has further been branched into
North America and Latin America, with the North American market divided into
the US and Canada. The European diabetic ulcer treatment market has been
categorized as Western Europe and Eastern Europe. The Western European market
has further been classified as Germany, France, the UK, Italy, Spain, and the
rest of Western Europe. The diabetic ulcer treatment market in Asia-Pacific has
been segmented into Japan, China, India, South Korea, Australia, and the rest
of Asia-Pacific. Due to the increasing patient pool of diabetic ulcer treatment
and technological advancements in the healthcare sector, Asia-Pacific is
expected to be the fastest-growing. The diabetic ulcer treatment market in the
Middle East & Africa has been divided into the Middle East and Africa.
Browse Complete Report :https://www.marketresearchfuture.com/reports/diabetic-ulcer-treatment-market-8360
Segmentation
The global diabetic ulcer treatment market has been
segmented based on type, treatment, and end user.
The market, based on type, has been divided into foot
ulcer, mouth ulcer, and others. The foot ulcer segment is further sub-segmented
in neuropathic ulcers, neuro-ischemic ulcers, and ischemic ulcers. The foot
ulcer segment holds the major share of the diabetic ulcer treatment market. The
proportion of neuropathic ulcers, neuro-ischemic ulcers, and ischemic ulcers
shown by a study are 54%, 34%, and 10% respectively. Some factors that mainly
cause this ulcer are low awareness, low economic position, ignorance towards
foot ulcer, and others. The end user segments of the market are
hospitals and clinics, ambulatory surgical centers, academic and research
organizations, and others. The hospitals and clinics segment is expected to
hold the largest share of the market as these centers are the primary locations
for patients receiving ulcer treatments and surgery.
Key Players
Some
of the key players in the global diabetic ulcer treatment market are Smith
& Nephew PLC (UK), Integra LifeSciences Corporation (US), SANUWAVE Health,
Inc. (US), Cardinal Health (US), ACELITY L.P. INC. (US), ConvaTec Group PLC
(UK), Organogenesis Inc. (US), Mölnlycke Health Care AB (Sweden), Essity
Aktiebolag (Sweden), 3M (US), and B. Braun Melsungen AG (Germany).
Market Drivers
- Increasing geriatric population
- Rise in the prevalence rate of diabetic
foot ulcers. One of the most common complications associated with diabetes
is diabetic foot ulcerations. It has a global annual incidence rate of
6.3%.
- The upsurge in the adoption of technological
advancements in wound care products
- Robust pipeline in diabetic ulcer
treatment
- Rising patient population and
advancement in health care infrastructure
No comments:
Post a Comment